title: Platelet Reactivity Unit in Predicting Risk of Bleeding in Patients Undergoing Coronary Artery Bypass Graft Surgery.
abstract: Bleeding is a common complication of cardiac surgery, accounting for a significant proportion of the total transfusions performed in the United States and Europe. The relationship between platelet reactivity, bleeding, and other adverse events after coronary artery bypass graft surgery (CABGS) has been incompletely characterized. This study investigated the relationship between platelet reactivity and bleeding as a clinical outcome after successful CABGS. A total of 238 patients who underwent CABGS were retrospectively followed for postoperative bleeding. Platelet reactivity unit (PRU) values for all patients were obtained preoperatively to assess the platelet reactivity. The data showed that a range of 180-200 PRU suggests the likelihood of bleeding after CABGS (P = 0.004), with a statistically significant association only for dual antiplatelet therapy with aspirin and clopidogrel. In conclusion, by using PRU values as a method to assess platelet reactivity and antiplatelet responsiveness, our findings suggest that it may be possible to stratify patients undergoing CABGS for the risk of postoperative bleeding particularly patients on dual antiplatelet therapy.
authors.affiliation: 1Department of Medicine, Saint Joseph's Regional Medical Center/New York Medical College, Paterson, NJ; 2Department of Medicine, Saint Michael's Medical Center/New York Medical College, Newark, NJ; and 3Cardiology Division, Westchester Medical Center/New York Medical College, Valhalla, NY.
authors.forename: Zaid
authors.initials: Z
authors.lastname: Altheeb
authors.forename: Ahmad
authors.initials: A
authors.lastname: Sbitan
authors.forename: Martin
authors.initials: M
authors.lastname: Shabiah
authors.forename: Vincent
authors.initials: V
authors.lastname: Debari
authors.forename: Aiman
authors.initials: A
authors.lastname: Hamdan
authors.forename: Mahesh
authors.initials: M
authors.lastname: Bikkina
authors.forename: Fayez
authors.initials: F
authors.lastname: Shamoon
authors.forename: Wilbert S
authors.initials: WS
authors.lastname: Aronow
mesh_terms: D000368:Aged; D001241:Aspirin / Q000008:administration & dosage / Q000009:adverse effects; D016063:Blood Loss, Surgical; D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism*; D001803:Blood Transfusion / Q000706:statistics & numerical data; D000077144:Clopidogrel; D001026:Coronary Artery Bypass / Q000009:adverse effects / Q000379:methods*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D019106:Postoperative Hemorrhage / Q000453:epidemiology* / Q000209:etiology; D012189:Retrospective Studies; D012307:Risk Factors; D013988:Ticlopidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives
chemical_list: D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin